Exhibit 1 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. MA-PD is Medicare Advantage Prescription Drug Plan. Analysis includes non-LIS.

Slides:

Advertisements

Similar presentations

Optima Medicare (PPO) Plans CY Medicare Medicare is a Federal health insurance program for those age 65 or older or individuals at any age who have.

Advertisements

THE COMMONWEALTH FUND Deductibles Offered by Medicare Stand-Alone Prescription Drug Plans, 2006 and 2007 $0 58% of plans $50-$100 8% of plans $250 34%

Exhibit 1. Estimated Source of Insurance Coverage, 2014 Note: The number of uninsured in 2014 was calculated using CPS estimates for 2013 minus an estimated.

Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.

New York State EPIC Program January 2012 Changes.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.

Medicare, Health Reform, and You. Don’t Worry! The benefits that Medicare guarantees will not change.

Medicare and the New Prescription Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser.

Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family Foundation for NASI Annual Conference.

Nearly one in four Medicare beneficiaries had a Medigap policy as a supplemental source of coverage in 2010 Multiple Sources of Coverage (without Medigap)

MEDICARE PART D: PAST AND PRESENT Juliette Cubanski, Ph.D. Associate Director, Program on Medicare Policy The Henry J. Kaiser Family Foundation MAPRx Congressional.

Exhibit 1 NOTE: *Amount corresponds to the estimated catastrophic coverage limit for non-low-income subsidy enrollees ($6,734 for LIS enrollees), which.

Medicare Modernization Act, Part D Prescription Drug Benefit Presentation for County Program Administrators September 1, 2005.

Figure 1 NOTE: Tests found no statistical difference from estimate for the previous year shown (p

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential.

MEDICARE PRESCRIPTION DRUG BENEFIT Presented by Juliette Cubanski, Ph.D. Principal Policy Analyst Medicare Policy Project The Henry J. Kaiser Family Foundation.

1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?

Medicare in Minnesota 2012 Your Medicare: Making the Best Possible Decisions October 2011 Presented by Stephanie Minor Senior LinkAge Line® Program Consultant.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Roy Trudel, CMSO National Eligibility Workers Association 07/12/05.

INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential.

Medicare: An Overview September 30, 2014 Society for Financial and Professional Development 7 th Annual Financial Literacy Leadership Conference Christina.

Slide -1 Medicare Prescription Drug Benefit Denise S. Stanley, Pharm.D. Atlanta Regional Office Centers for Medicare & Medicaid Services March 17, 2006.

Medicare Advantage Overview Diane Rowland, Sc.D. Executive Vice President Kaiser Family Foundation Alliance for Health Reform July 16, 2007.

NOTES: Numbers may not sum to total due to rounding. People with disabilities under age 65 were not eligible for Medicare prior to SOURCE: Centers.

Medicare Part D and the Financial Protection of the Elderly Gary V. Engelhardt Syracuse University Jonathan Gruber MIT.

Medicare Unit 7. Medicare Part A Payment Plan Beneficiary Pays (2009) Hospital Stays 1-60 days $ days $267/day days $534/day 151+ days.

1 Factors Associated with Regional Variation in Medicare Part D Prescription Drug Plan Participation and Beneficiary Leslie M. Greenwald, Ph.D. Principal.

Chartpack Medicare Prescription Drug Benefit Progress Report: Findings from the Kaiser/Commonwealth/Tufts-New England Medical Center 2006 National Survey.

All CIGNA Medicare 2009 plan designs described in this document are pending government approval and are therefore subject to change. For producer use only.

Medicare Part D Symposium Thursday, September 1, 2005 Sacramento, CA Cathy Senderling Senior Legislative Advocate, CWDA.

The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.

THE COMMONWEALTH FUND Medicare Part D: What Are The Concerns? Stuart Guterman Director, Program on Medicare’s Future The Commonwealth Fund Association.

1 Variation in Medicare Part D Prescription Drug Plan Benefits, 2006 Leslie M. Greenwald, Ph.D. Principal Scientist RTI, International.

Return to Tutorials Tricia Neuman, Sc.D. Director, Medicare Policy Project Vice President, Kaiser Family Foundation For KaiserEDU June 2009 Medicare 101:

0 Beneficiary Choices in Medicare Part D and Plan Features in 2006 Supported by PhRMA September 13, 2006.

Avalere Health LLC | The intersection of business strategy and public policy The Potential Impact of the New Prescription Drug Benefit on Medicare Beneficiaries.

Minimizing Part D Costs for Medicare Beneficiaries: “Not Just a Drop in the Bucket” Rajul A. Patel, PharmD, PhD, Kate M. O'Dell, PharmD, Kim-Anh Vo, PharmD.

Rajul A. Patel, PharmD, PhD, Kate M. O'Dell, PharmD, Kenneth Wang, Pharm D Candidate, Shu Lu, Pharm D Candidate, Tiffany Chu, Pharm D Candidate, Kim-Anh.

Slide -1 Medicare Prescription Drug Coverage Atlanta Regional Office Centers for Medicare & Medicaid Services September 12, 2005.

“For the vast majority of seniors, the new benefit is working.” -Mark McClellan, CMS, February 2006 "It's a disaster, Medicare Part D - D is unfortunately.

MEDICARE ADVANTAGE: WHAT CONGRESS INTENDED? by Marsha Gold, Sc.D. Senior Fellow Mathematica Policy Research June 3, 2007 For presentation at Panel on “Medicare.

Exhibit 1 NOTE: Excludes SNPs, employer-sponsored (i.e., group) plans, demonstrations, HCPPs, PACE plans, and plans for special populations (e.g., Mennonites).

Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.

The Future of Medicare Advantage The Heritage Foundation September 10, 2008 James C. Capretta Fellow, Ethics and Public Policy Center

1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.

Karissa A. Laur Director, Prescription Assistance Programs Coordinating Patient Assistance Programs with Medicare Part D: A Manufacturer’s Perspective.

Chapter 7: Medicare Part D Prescription Drug Coverage in Patients with Chronic Kidney Disease 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 12: Part D Prescription Drug Coverage in Patients with ESRD.

Exhibit 8.1 Number of Medicare Beneficiaries, Fiscal Years (a) Copyright 2011 by the Foundation of the American College of Healthcare Executives.

Avalere Health LLC | The intersection of business strategy and public policy Part D Plans and Specialty Products Presented by Lovisa Gustafsson.

MEDICARE PART D July MEDICARE PART D: OVERVIEW Part D provides prescription drug coverage for Medicare beneficiaries. Prescription drug plans compete.

Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.

State Responses to Medicare Part D Presented by: Kimberley Fox, Senior Policy Analyst, Institute for Health Policy Academy Health Annual Research Meeting.

Date of download: 5/28/2016 From: Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and Hyperlipidemia Ann.

Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.

CL This material has been created or produced by CLAIM with financial assistance, in whole or part, through a grant from the Administration for.

Total Medicare Spending in 2014 = $613.3 billion

Exhibit 1 Medicare Beneficiaries Spending 20 Percent or More of Income on Premiums and Care, by Poverty Level Percent of Medicare beneficiaries Note: FPL.

For a middle-age person, before tax credits, premiums for comparable coverage would be similar under each plan Annual individual market premium for a silver.

2018 Medicare Prescription Drug Benefit

Total U.S. prescription drug spending, in $ billions:

Total Medicare Private Health Plan Enrollment,

MMA, Private Plans, and Competition: Commercial Health Plan Response to MMA November 1, 2005 David F. Ogden, F.S.A. Milliman, Inc.

The Third National Medicare Congress David B. Snow, Jr.

Cost Sharing Under Part D: Impact on Beneficiaries with the Standard Benefit Bruce Stuart, PhD Director, Peter Lamy Center on Drug Therapy and Aging.

Medicare Part D: What Are The Concerns?

Proprietary Information-Do Not Share

Estimated Annual Premiums Under Different Scenarios, 2010

Presented by Tricia Neuman, Sc.D.

Presentation transcript:

Exhibit 1 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. MA-PD is Medicare Advantage Prescription Drug Plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP or MA-PD in one or more annual enrollment period from 2006 to 2010; estimates are averaged across four annual enrollment periods, See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Most Non-LIS Medicare Part D Enrollees Did Not Switch Plans Voluntarily During an Open Enrollment Period,

Exhibit 2 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. MA-PD is Medicare Advantage Prescription Drug Plan. See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Switching Rates Among Non-LIS Part D Enrollees Were Similar Across Four Annual Enrollment Periods and Different Plan Types

Exhibit 3 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP continuously from 2006 to 2010 (n=313,418). See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Among Non-LIS Part D Enrollees Continuously Enrolled in PDPs From 2006 to 2010, 7 out of 10 Never Voluntarily Switched Plans

Exhibit 4 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP continuously from 2006 to 2010 (n=313,418). See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Share of enrollees: 100%77.1%16.7%5.1%1.1% Switching Rates In Were Higher Among Non-LIS PDP Enrollees Who Previously Switched Plans and Increased With the Number of Prior Switches Number of Switches Prior to the Enrollment Period

Exhibit 5 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP in one or more annual enrollment period from 2006 to 2010; excludes those who switched to a Medicare Advantage drug plan; estimates are averaged across four annual enrollment periods, See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, A Larger Share of Non-LIS PDP Enrollees Who Switched Plans Had Lower Costs in Year 2 Than in Year 1, Compared to Non-Switchers, Premiums Out-of-pocket drug costs

Exhibit 6 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP in one or more annual enrollment period from 2006 to 2010; excludes those who switched to a Medicare Advantage drug plan; estimates are averaged across four annual enrollment periods, See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Switching Rates Were Higher Among Non-LIS PDP Enrollees Facing Larger Premium Increases, Compared to Other Enrollees, Change in Monthly PDP Premium From Year 1 to Year 2 Share of enrollees 100%13.0%66.6%16.6%3.8%

Exhibit 7 Share of enrollees 100%3.6%83.5%12.7% NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP in the annual enrollment period (n=438,006); excludes those who switched to a Medicare Advantage drug plan. See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Switching Rates Were Higher Among Non-LIS PDP Enrollees Facing a Higher Deductible, Compared to Other PDP Enrollees, Change in PDP Deductible From Year 1 to Year 2

Exhibit 8 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. Analysis includes non-LIS Medicare Part D enrollees in a PDP in one or more annual enrollment period from 2006 to 2008; excludes those in PDPs adding gap coverage and those who switched to a Medicare Advantage drug plan. See Appendix 1 for full methodology. SOURCE: Georgetown/NORC/Kaiser Family Foundation analysis of Medicare Beneficiary Summary Files and Plan Characteristics Files, Switching Rates Were Higher Among Non-LIS PDP Enrollees Who Lost Brand-Name Gap Coverage, Compared to Other Enrollees, Share of enrollees 100%5.0%89.0%100%1.3% 97.8%